Open AccessHow Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
Author(s) -
Araceli Muñoz-Garach,
María Molina-Vega,
Francisco J. Tinahones
Publication year - 2016
Publication title -
diabetes therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.907
H-Index - 33
ISSN - 1869-6961
DOI - 10.1007/s13300-016-0214-7
Subject(s) - medicine , insulin glargine , pharmacodynamics , pharmacokinetics , diabetes mellitus , basal (medicine) , type 2 diabetes , insulin , population , insulin analog , triglyceride , endocrinology , gliclazide , pharmacology , cholesterol , human insulin , environmental health
Lack of control in diabetic patients has stimulated the development of new insulin analogues. One of these was basal insulin peglispro (BIL) or LY2605541; it had a large hydrodynamic size, flat pharmacokinetic profile, half life of 2-3 days and acted preferably in the liver.